SPRY stock drops 24% as Neffy misses July 2026 wins

After-hours slide follows payer update

Shares of ARS Pharmaceuticals (NASDAQ: SPRY) fell sharply in extended trading after the company said it did not secure any new major commercial insurance coverage for its neffy nasal spray in the coverage cycle effective July 1, 2026. The update mattered because investors were positioned for fresh formulary wins with large commercial insurers during the latest review cycle. Instead, the company said there were no significant new commercial coverage decisions that will take effect on July 1. The result was an immediate reset of expectations around near-term payer expansion for neffy. ARS said discussions with payers are still ongoing, but the lack of confirmed additions disappointed markets.

What the stock did: regular session vs extended trading

SPRY closed the regular session at $10.54, up 2.53%. After the update, the stock traded down to about $1.00 in after-hours, a decline of roughly 24%. Reports around the move described the drop as over 23% after-hours, reflecting the same sharp sell-off. The price action highlighted how sensitive the stock remains to coverage news for neffy. ARS Pharmaceuticals also entered the update with a year-to-date decline of about 8%, adding to investor focus on catalysts that could widen access.

No new commercial formulary additions for July 1 cycle

ARS Pharmaceuticals said no new commercial formulary additions or coverage decisions were issued for neffy in the July 1, 2026 cycle. That directly undercut the market’s expectation of “formulary wins” with large commercial insurers during this coverage window. The company stated it will continue discussions with payers for potential future inclusion. It also said neffy remains broadly accessible to commercially insured patients through existing coverage. Still, without incremental commercial wins, the pace of access expansion appears unchanged heading into July.

Why commercial coverage matters for patient costs

The company’s commercial update has practical implications for out-of-pocket expenses. Without broader commercial coverage, many patients may continue to face higher out-of-pocket costs. Some may also rely on ARS Pharmaceuticals’ cash-pay option rather than insurer reimbursement. ARS said it recently introduced a retail cash option and described it as priced comparably to other epinephrine products. The company’s positioning suggests it is trying to limit demand disruption even when payer decisions lag.

Medicaid win: Florida adds Neffy effective July 1

Alongside the commercial setback, ARS reported additional Medicaid coverage progress, including in Florida. The company said Florida added neffy to its unrestricted Medicaid formulary effective July 1, 2026. This was framed as a positive development in the update, even as commercial coverage remained unchanged. The company has indicated that Medicaid coverage is expanding across multiple states, with Florida specifically highlighted. However, the broader market narrative in trading focused more on commercial insurer outcomes.

Company stance: negotiations ongoing into H2

ARS said it remains in active negotiations with several large payers and stays focused on expanding payer access in the second half of the year. The language indicates that the July 1 cycle did not end the conversation with payers, but it did not deliver new decisions in time for that effective date. Some payer talks were described as extending into mid-June. The company reiterated its intent to keep working with remaining payers. For investors, the key point was timing: negotiations continue, but the expected near-term coverage inflection did not arrive.

Financial and pipeline updates included in the release

Beyond coverage, ARS Pharmaceuticals also provided financial and business updates. The company cut its 2026 cash-based operating expense outlook (excluding cost of goods sold) to about $148 million. It reaffirmed its path to a 2027 cash-flow breakeven. ARS also said interim data from a Phase 2b clinical trial in chronic spontaneous urticaria (CSU) is expected in the fourth quarter of 2026. These items provided context on spend discipline and upcoming milestones, even though the trading reaction centred on payer coverage.

Regulatory and licensing milestones referenced around Neffy

ARS has also pointed to progress in multiple markets outside the US. In Japan, ARS Pharma entered an exclusive licensing agreement with Alfresa Holdings, which holds rights to commercialize neffy, and Japanese regulators have approved neffy 1 mg and 2 mg doses for emergency treatment of allergic reactions (anaphylaxis) in adults and children who weigh more than 15 kilograms. In China, ARS has an exclusive licensing agreement with Pediatrix Therapeutics, and regulatory approval was granted for neffy 2 mg for adults and children who weigh 30 kg or more. Separately, ARS announced Health Canada approval of neffy 2 mg for emergency treatment of allergic reactions (anaphylaxis) in adults and children who weigh at least 30 kg. The company has also announced FDA approval to remove the age requirement for neffy 1 mg, allowing use in all children and adults who weigh at least 33 lbs (15 kg) for Type 1 allergic reactions, including anaphylaxis.

Retail sentiment indicators and message volume

Retail discussion also picked up after the update. On Stocktwits, sentiment around SPRY remained in “bearish” territory over the past 24 hours. At the same time, message volume reportedly rose from “low” to “high” levels. The combination suggested heightened retail attention as traders reacted to the payer outcome. Commentary referenced both scepticism about neffy’s near-term trajectory and views that the after-hours sell-off may have been an overreaction.

Key numbers at a glance

Market impact and why this update moved the stock

The after-hours decline showed investors were focused on commercial payer expansion as a near-term driver of neffy uptake. The company’s statement that there were no new major commercial formulary additions for the July 1 cycle removed a specific anticipated catalyst. While Medicaid additions, including Florida, were positive, they did not offset the market’s emphasis on commercial coverage breadth. ARS also highlighted existing commercial access and a new cash-pay path, which may help maintain availability even without fresh payer wins. But the reaction suggested the market wanted confirmation of expanded commercial reimbursement rather than continued negotiations.

Conclusion

ARS Pharmaceuticals’ June update delivered a clear message for July 1, 2026: no new major commercial coverage decisions for neffy, even as talks with large payers continue. The company balanced that with a Florida Medicaid formulary addition effective July 1 and an updated 2026 cash-based operating expense outlook of about $148 million. Investors will likely watch for any future payer inclusions in the second half of the year, alongside the company’s stated path toward 2027 cash-flow breakeven and expected Phase 2b CSU interim data in Q4 2026.